Literature DB >> 277719

Case-control study of antihypertensive and diuretic use by women with malignant and benign breast lesions detected in a mammography screening program.

R R Williams, M Feinleib, R J Connor, N L Stegens.   

Abstract

A significant but low-level association (relative odds, 2.0; P less than 0.05) was observed between the occurrence of breast cancer and the use of rauwolfia derivatives for 5 or more years in the study of 481 breast cancer cases and 1,268 controls from a joint national mammography screening project of the National Cancer Institute and the American Cancer Society. This association was confined to women over age 50 years who were also heavier than average. No confounding effects could be held responsible for this association after adjustment was made for variables such as presence of hypertension, weight, age at first pregnancy, and other breast cancer risk factors. Other antihypertensive and diuretic drugs as well as multiple drug use also exhibited some suggestive associations with breast cancer. Another group of 421 women with benign lesions at breast biopsy were also compared to the 1,268 controls. They showed a significant association between benign lesions and use of thiazides for 5 or more years (relative odds, 2.4; P less than 0.001) whether employed to treat edema or hypertension. Other antihypertensive and diuretic agents also seemed to show this association, but most of them were being used together with thiazides.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 277719

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  7 in total

Review 1.  Reserpine: a relic from the past or a neglected drug of the present for achieving cost containment in treating hypertension?

Authors:  G J Magarian
Journal:  J Gen Intern Med       Date:  1991 Nov-Dec       Impact factor: 5.128

2.  Stress and relapse of breast cancer.

Authors:  L Israël
Journal:  BMJ       Date:  1989-04-15

Review 3.  Carcinogenicity of antihypertensive therapy.

Authors:  Ehud Grossman; Franz H Messerli; Uri Goldbourt
Journal:  Curr Hypertens Rep       Date:  2002-06       Impact factor: 5.369

Review 4.  Carcinogenicity of cardiovascular drugs.

Authors:  E Grossman; F H Messerli; U Goldbourt
Journal:  Curr Hypertens Rep       Date:  1999-06       Impact factor: 5.369

5.  Understanding genetic and environmental risk factors in susceptible persons.

Authors:  R R Williams
Journal:  West J Med       Date:  1984-12

6.  Hydralazine use in relation to cancers of the lung, colon, and rectum.

Authors:  D W Kaufman; J P Kelly; L Rosenberg; P D Stolley; M E Warshauer; S Shapiro
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

7.  Hazardous substances, the environment and public health: a statistical overview.

Authors:  W G Hunter; J J Crowley
Journal:  Environ Health Perspect       Date:  1979-10       Impact factor: 9.031

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.